J Rheum Dis.  2015 Dec;22(6):356-365. 10.4078/jrd.2015.22.6.356.

Comparative Efficacy and Safety of Febuxostat and Allopurinol in the Treatment of Hyperuricemia: A Bayesian Network Meta-analysis

Affiliations
  • 1Division of Rheumatology, Department of Internal Medicine, Korea University Medical Center, Korea University College of Medicine, Seoul, Korea. lyhcgh@korea.ac.kr

Abstract


OBJECTIVE
The aim of this study was to assess the relative urate-lowering efficacy and safety of febuxostat and allopurinol in hyperuricemic patients with or without gout.
METHODS
Randomized controlled trials (RCTs) examining the efficacy and safety of febuxostat compared to allopurinol or placebo in hyperuricemic patients with/without gout were included in this Bayesian network meta-analysis.
RESULTS
Eight RCTs including 4,099 patients met the inclusion criteria. The number of subjects achieving a serum urate (sUA) level <6.0 mg/dL was significantly higher in the febuxostat 120 mg and 80 mg groups than in the allopurinol (100 to 300 mg) group (odds ratio [OR] 7.17, 95% credible interval [CrI] 3.86 to 14.09; OR 3.49, 95% CrI 1.97 to 5.91, respectively). However, achievement of the target sUA level was comparable between febuxostat 40 mg and allopurinol. Ranking probability based on surface under the cumulative ranking curve (SUCRA) indicated that febuxostat 120 mg had the highest probability of being the best treatment for achieving the target sUA (SUCRA=0.9973), followed by febuxostat 80 mg (SUCRA=0.752), febuxostat 40 mg (SUCRA=0.4289), allopurinol (SUCRA=0.3217), and placebo (SUCRA=0). In contrast, no significant difference in safety based on the number of withdrawals due to adverse events was observed among the 5 interventions.
CONCLUSION
Febuxostat 80 mg and 120 mg were more efficacious than allopurinol (100 to 300 mg), and febuxostat 40 mg and allopurinol were comparable in urate-lowering efficacy. The safety of febuxostat at all doses was comparable with that of allopurinol.

Keyword

Febuxostat; Allopurinol; Gout; Meta-analysis

MeSH Terms

Allopurinol*
Gout
Humans
Hyperuricemia*
Uric Acid
Febuxostat
Allopurinol
Uric Acid

Figure

  • Figure 1. Evidence network diagram of network meta-analysis comparisons. The width of each edge is proportional to the number of randomized controlled trials comparing each pair of treatments, and the size of each treatment node is proportional to the number of randomized participants (sample size).(A) Febuxostat 40 mg. (B) Febuxostat 80 mg. (C) Febuxostat 120 mg. (D) Allopurinol. (E) Placebo.

  • Figure 2. League tables showing the results of the network metaanalyses comparing the effects of all drugs including odds ratio (OR) and 95% credible intervals. (A) Efficacy; OR >1 means the top-left treatment is better. (B) Safety; OR <1 means the top-left treatment is better.

  • Figure 3. Bayesian network meta-analysis results of randomized controlled studies on the relative efficacy (A) and safety (B) of febuxostat, allopurinol, and placebo, respectively. CrI: credible interval, OR: odds ratio.

  • Figure 4. Inconsistency plots for efficacy (A) and safety (B) of febuxostat, allopurinol, and placebo. Plot of the posterior mean deviance contribution of individual data points for the consistency model (horizontal axis) and the unrelated mean effects model (vertical axis), along with the line of equality.


Cited by  1 articles

Rising a Novel Weapon in the War against Gout and Hyperuricemia
Jung Soo Song
J Rheum Dis. 2016;23(1):1-3.    doi: 10.4078/jrd.2016.23.1.1.


Reference

1. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol. 2002; 14:281–6.
Article
2. Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003; 349:1647–55.
3. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 65:1312–24.
Article
4. Perez-Ruiz F, Lioté F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum. 2007; 57:1324–8.
Article
5. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984; 76:47–56.
Article
6. Arellano F, Sacristán JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993; 27:337–43.
Article
7. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005; 76:1835–47.
Article
8. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: a twen-ty-eight-day, multicenter, phase II, randomized, doubleblind, placebo-controlled, doseresponse clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005; 52:916–23.
Article
9. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353:2450–61.
Article
10. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008; 59:1540–8.
Article
11. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12:R63.
Article
12. Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, et al. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-pu-rine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011; 17(4 Suppl 2):S13–8.
13. Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, et al. Placebo-controlled double-blind doseresponse study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study. J Clin Rheumatol. 2011; 17(4 Suppl 2):S35–43.
14. Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, et al. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011; 17(4 Suppl 2):S19–26.
15. Park SH, Song YW, Park W, Koh EM, Yoo B, Lee SK, et al. The urate-lowering efficacy and safety of febuxostat in Korean patients with gout. J Rheum Dis. 2013; 20:223–30.
Article
16. Elion GB, Yü TF, Gutman AB, Hitchings GH. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med. 1968; 45:69–77.
Article
17. Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, et al. European League Against Rheumatism. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011; 123(6 Suppl 1):3–36.
Article
18. Ye P, Yang S, Zhang W, Lv Q, Cheng Q, Mei M, et al. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. Clin Ther. 2013; 35:180–9.
Article
19. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG. Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep. 2011; 38:3643–51.
Article
20. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG. PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis. Rheumatol Int. 2007; 27:827–33.
Article
21. Catalá-López F, Tobías A, Cameron C, Moher D, Hutton B. Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int. 2014; 34:1489–96.
Article
22. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005; 331:897–900.
Article
23. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977; 20:895–900.
Article
24. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17:1–12.
Article
25. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. Ann Intern Med. 2009; 151:264–9.
Article
26. Brown S, Hutton B, Clifford T, Coyle D, Grima D, Wells G, et al. A Microsoft-Excel-based tool for running and critically appraising network metaanalyses: an overview and application of NetMetaXL. Syst Rev. 2014; 3:110.
Article
27. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multi-ple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011; 64:163–71.
Article
28. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013; 33:641–56.
29. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012; 3:98–110.
Article
30. van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Res Synth Methods. 2012; 3:285–99.
Article
31. Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012; 64:256–61.
Article
32. Jackson RL, Hunt B, MacDonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients ≥ 65 years of age. BMC Geriatr. 2012; 12:11.
Article
33. Wells AF, MacDonald PA, Chefo S, Jackson RL. African American patients with gout: efficacy and safety of febuxostat vs allopurinol. BMC Musculoskelet Disord. 2012; 13:15.
Article
34. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009; 36:1273–82.
Article
35. Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, et al. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-se-lective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. J Clin Rheumatol. 2011; 17(4 Suppl 2):S44–9.
36. Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009; 48:188–94.
Article
37. Goldfarb DS, MacDonald PA, Hunt B, Gunawardhana L. Febuxostat in gout: serum urate response in uric acid over-producers and underexcretors. J Rheumatol. 2011; 38:1385–9.
Article
38. Sezai A, Soma M, Nakata K, Hata M, Yoshitake I, Wakui S, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circ J. 2013; 77:2043–9.
Article
39. White WB, Chohan S, Dabholkar A, Hunt B, Jackson R. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. Am Heart J. 2012; 164:14–20.
Article
40. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002; 47:356–60.
Article
Full Text Links
  • JRD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr